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Too Many Roads Not Taken in Biomarker Discovery:
The Story of Missing Tools Sean A. Agger * The draft sequence of the human genome was completed in 2000, and scientists, funding agencies, and industry all claimed at the time that this groundbreaking accomplishment would translate into benefits for modern medicine by identifying "druggable" protein targets. Surprisingly, today a majority of the research remains focused on a small number of proteins that were identified before the sequencing of the human genome. The fact that protein research has not changed despite the "genomic revolution" highlights 3 important questions. First, has the Human Genome Project produced the "fruits" we thought it would? Second, why do scientists continue to study the same proteins that were identified in the pre-human genome era? Finally, how can we encourage the study of the novel proteins that have been revealed as a result of the Human Genome Project? These questions and some potential solutions are discussed by Edwards et al. in the commentary "Too Many Roads Not Taken" (1 ) . These authors focused on research surrounding kinases, nuclear receptors, and ion channels, all of which are major contributors in the development of disease and are key targets for drugdiscovery programs. In a bibliometric analysis, Edwards et al. discovered a consistent pattern of research activity in these protein families over the past 20 years suggesting that the newly available genomic data have not substantially influenced biomedical investigation. Surprisingly, 50 of the protein kinases that were most commonly referenced before creation of the genome draft still make up an overwhelming number of the citations in the postgenomic era. This observation holds true although Ͼ500 kinases have now been an-notated and hundreds of them have been linked to disease. The story for nuclear receptors is similar, with the most commonly cited proteins remaining the same over the last 10 years. In fact, the 6 most cited nuclear receptors received 71% of the citations in 1999, and the same 6 receptors continued to garner 72% of the citations in 2009, again highlighting the challenge researchers have had in using the genomic data.
A frequent but false assumption is that previous research has implicated these highly cited proteins as being central to disease and that all other proteins have been shown to be irrelevant.
the focus remained on the same 3 nuclear receptors that have remained the most highly cited since the early 1990s.
Edwards et al. hypothesize that the continued bias in protein research is due to several factors, perhaps the most important being the lack of research tools. Interestingly, shifts in protein research are likely to be driven less by scientific hypothesis and more by the emergence of novel chemical reagents, such as chemical inhibitors, antibodies, and recombinant proteins. One remarkable example occurred after the commercial availability of high-quality chemical probes for a subset of nuclear receptor proteins. This novel tool caused a dynamic shift in focus from the 37 nuclear receptors originally linked to disease back in the 1990s down to just 8 nuclear receptors. From a genetics perspective, these 8 receptors were no more or less important than the other 29; however, the sheer availability of the probe created a selection bias that led to the abandonment of the other proteins. It is clear that the availability of protein-specific research tools will be critical to address the current bias in protein research.
There are a number of things we can do to take full advantage of the genomic data and help solve the research bias. It will be essential to direct funding toward projects focused on developing research tools, much as the high-energy physics community does. The biological community has traditionally looked down on this type of work, but it will be crucial for promoting the study of novel proteins. Furthermore, we will have to take this approach with the knowledge that tool development is considered "risky science" and does not have a high likelihood of success. Many scientists also understand that the current funding and peer-review process is risk averse. Young faculty and graduate students face a great amount of pressure to generate results within a short time span, a situation that encourages the use of previously well-established (and not novel) systems and continues to reinforce this research bias. One solution to this problem is to fund innovative and creative investigators for longer periods of time. That would encourage more exploration and risk with their research programs and facilitate the study of new and uncharacterized proteins.
It is clear that aspects of the current system have allowed the introduction of substantial bias into our research on proteins and the genome, although we have unbiased genetic methods and tools that have linked many unstudied proteins to disease. Critical for moving forward will be for the biomedical community to promote the study and characterization of these contemporary proteins that are now hidden in plain sight. Such steps will be crucial to take full advantage of the findings of the Human Genome Project and to reap the benefits from this remarkable achievement.
